四价脑膜炎球菌白喉类毒素结合疫苗常规使用上市后安全性监测研究
本研究为观察性回顾性研究,纳入2005年4月至2006年4月Kaiser Permanente Northern California(KPNC)所有接种MenACWY-D的31561名成员,监测接种后6个月内的非计划住院、急诊就诊及选定的临床结局。采用自身对照计算发病率比(IRR),并与匹配对照比较。结果显示未发现MenACWY-D的安全性担忧,常规接种未与意外安全风险相关。
要点
- 研究期间共31561名KPNC患者接种MenACWY-D,其中>99%为11-55岁。
- 21个结局的IRR显著升高,44个结局的IRR显著降低;病历回顾未提示与疫苗相关。
- 研究未发现MenACWY-D的安全性担忧,常规接种未与意外安全风险相关。
核心结论
- 本研究未发现MenACWY-D的安全性担忧,并表明常规接种MenACWY-D未与意外安全风险相关。
研究设计与样本
- 观察性回顾性研究,纳入研究期间所有接种MenACWY-D的KPNC成员,共31561人,其中>99%为11-55岁。
主要发现
- 2005年4月至2006年4月,31561名KPNC患者接种MenACWY-D,其中>99%为11-55岁。
- 总体有21个结局的IRR显著升高,44个结局的IRR显著降低。
- 对IRR显著升高的结局进行病历回顾,未提示与MenACWY-D存在任何关系。
- 研究调查者认为2例严重不良事件可能与接种相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Menactra® vaccine (MenACWY-D) was licensed in the United States in 2005 for persons 11-55years of age. The aim of this study was to assess the safety of MenACWY-D administered as part of routine clinical care to patients at Kaiser Permanente Northern California (KPNC). METHODS: This was an observational, retrospective study that included all KPNC members who received MenACWY-D during the study period. We monitored all vaccine recipients for non-elective hospitalizations, emergency department visits, and selected outcomes captured in the clinic setting (Bell's palsy, seizures, neuritis, Guillain-Barré syndrome, encephalopathy, encephalitis, epilepsy, transverse myelitis, multiple sclerosis, hypersensitivity reactions, idiopathic thrombocytopenic purpura, diabetes, arthritis, hemolytic anemia, collagen-vascular disease) through 6months after vaccination. Using vaccine recipients as their own controls, we calculated incidence rate ratios (IRRs) of outcomes during the post-vaccination risk interval and compared these with rates during a comparison interval more remote from vaccination. We also compared rates of outcomes in MenACWY-D recipients with those in matched controls who received selected vaccines in the prior year. We reviewed medical records for selected outcomes. RESULTS: From April 2005 through April 2006, 31,561 KPNC patients (>99% of whom were 11-55years of age) received MenACWY-D. Overall, there were 21 outcomes with significantly elevated IRRs and 44 outcomes with significantly reduced IRRs. Medical record review of outcomes with significantly elevated IRRs did not suggest any relationship with MenACWY-D. Two serious adverse events were considered possibly related to vaccination by the study investigator. CONCLUSIONS: This study did not detect any safety concerns following MenACWY-D and provides reassurance that MenACWY-D administered as part of routine care was not associated with unexpected safety risks. ClinicalTrials.gov Identifier is NCT00254995.
引用
- Hansen J, Zhang L, Klein NP, et al. Post-licensure safety surveillance study of routine use of quadrivalent meningococcal diphtheria toxoid conjugate vaccine. Vaccine. 2017. PMID: 28941623. doi:10.1016/j.vaccine.2017.09.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。